Kiniksa expects 2024 ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million. Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
- Kiniksa announces development indication for abiprubart
- Kiniksa Pharmaceuticals Advances Clinical Trials and Ensures Positive Cash Flow
- Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
- Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
